NCT00480363: Phase 3: Revlimid / Dex ( ReDex) VS Observation in Smoldering MM (QUIREDEX)
Bortezomib before & after high-dose therapy in myeloma: phase III HOVON-65/GMMG-HD4 trial
NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating New Myeloma
NCT00507416: Phase 3: Velcade,Thalidomide, Dexamethasone Vs Velcade, Dexamethasone Vs VMP (UPFRONT)
NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
NCT00405756: Phase 3 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM
NCT00200681 : Phase 3- IFM 2005-01: Velcade/Dex Vs Vincristine/Adriamycin/Dex (VAD) for MM
NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
NCT00081939: UARK 2003-33, Total Therapy III
PMID 6546971: Effective treatment of advanced multiple myeloma refractory to alkylating agents
Single versus double autologous stem-cell transplantation for multiple myeloma
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM
IFM 9502 trial: 200 mg/m(2) melphalan Vs 8 Gy TBI + 140 mg/m(2) melphalan as conditioning Blood 2002
IFM trial: Conventional chemo or high-dose therapy and auto bone marrow transplantation - NEJM 1996
Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999
Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999
Results of autologous stem cell transplant in multiple myeloma patients with renal failure